A clinical-stage agent (23, 30), bintrafusp alfa was shown in preclinical models to reduce TGF-β–mediated tumor EMT (31), enhance the cytolytic ability of T and NK cells, and synergize with other immunotherapies to mediate tumor control (21, 26). The gene discussed is TGFB1; the disease is neoplasm.